drugset / Trial / NCT02183298

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male Volunteers

NCT02183298

Phase 1 Completed 36 enrolled Boehringer Ingelheim
RandomizedSingle-groupSingle-blindTreatment

Summary

Study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 1356 as formulation for intravenous administration

Timeline

Start
2006-05
Primary completion
2006-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Linagliptin Small molecule 0.5 mg
Subject Linagliptin Small molecule 5 mg
Subject Linagliptin Small molecule 10 mg

Indications

No indication recorded.